Moderna (NASDAQ:MRNA) Shares Up 3.6%

Shares of Moderna, Inc. (NASDAQ:MRNA) shot up 3.6% during trading on Monday . The company traded as high as $123.34 and last traded at $122.97. 420,548 shares were traded during trading, a decline of 90% from the average session volume of 4,178,165 shares. The stock had previously closed at $118.75.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several recent analyst reports. Oppenheimer lifted their price target on Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 12th. Evercore ISI reaffirmed an “in-line” rating and set a $120.00 price target on shares of Moderna in a research report on Thursday, June 27th. Piper Sandler reaffirmed an “overweight” rating and set a $214.00 price target on shares of Moderna in a research report on Thursday, June 27th. Jefferies Financial Group reiterated a “buy” rating and set a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. Finally, UBS Group boosted their price objective on Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $134.02.

Moderna Price Performance

The stock has a 50-day moving average price of $134.54 and a 200 day moving average price of $112.62. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. The business had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The business’s revenue was down 91.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.19 earnings per share. As a group, equities analysts predict that Moderna, Inc. will post -7.46 EPS for the current fiscal year.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 705 shares of Moderna stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $101.93, for a total value of $71,860.65. Following the sale, the chief financial officer now directly owns 5,048 shares of the company’s stock, valued at $514,542.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Moderna news, CFO James M. Mock sold 705 shares of the business’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $101.93, for a total transaction of $71,860.65. Following the transaction, the chief financial officer now owns 5,048 shares of the company’s stock, valued at $514,542.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $105.02, for a total value of $1,575,300.00. Following the transaction, the president now directly owns 1,486,241 shares in the company, valued at approximately $156,085,029.82. The disclosure for this sale can be found here. Insiders have sold 396,255 shares of company stock valued at $54,593,731 over the last ninety days. Insiders own 15.20% of the company’s stock.

Hedge Funds Weigh In On Moderna

Large investors have recently modified their holdings of the business. Quadrant Capital Group LLC raised its holdings in shares of Moderna by 7.5% in the 4th quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock valued at $266,000 after buying an additional 187 shares during the period. International Assets Investment Management LLC raised its holdings in shares of Moderna by 6,528.9% in the 4th quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock valued at $38,552,000 after buying an additional 381,808 shares during the period. abrdn plc raised its holdings in shares of Moderna by 477.5% in the 4th quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after buying an additional 399,843 shares during the period. Ontario Teachers Pension Plan Board purchased a new stake in shares of Moderna in the 4th quarter valued at $1,358,000. Finally, Hobbs Group Advisors LLC purchased a new stake in shares of Moderna in the 4th quarter valued at $664,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.